Mesa Laboratories CFO John Sakys Buys Shares

Mesa Laboratories, Inc.'s CFO, John Sakys, made a significant purchase of the company's stock. On June 18, 2026, Sakys bought 3,792 shares of Mesa Laboratories (NasdaqGS: MLAB) at an average price of $95.10 each, amounting to a total investment of $360,619. This transaction was not part of a pre-planned trading scheme.

Other Institutional Activity in Mesa Laboratories

Institutional investors have been active in Mesa Laboratories recently. LONG PATH PARTNERS LP significantly boosted its holdings by 178,360 shares, now holding 405,583 shares valued at approximately $35.9 million, reflecting a 78.5% increase. Meanwhile, BLACKROCK, INC. trimmed its position by 4,815 shares, maintaining 393,851 shares worth about $34.8 million, a slight 1.2% decrease. BOSTON PARTNERS expanded its stake by 55,335 shares, now holding 268,711 shares valued at around $23.8 million, a 25.9% increase. SELECT EQUITY GROUP, L.P. also increased its position by 29,450 shares, bringing its total to 235,885 shares worth $20.9 million, a 14.3% rise. Additionally, VANGUARD CAPITAL MANAGEMENT LLC opened a new position with 232,643 shares, valued at approximately $20.6 million.

Mesa Laboratories, Inc. Stock Down 27.1%

Shares of Mesa Laboratories, Inc. traded near $93.23 on Tuesday. The company has a market capitalization of approximately $515.1 million. It trades with a P/E ratio of 77.05 and a forward P/E of 7.60, indicating expectations of future earnings growth. The stock has a beta of 0.927, suggesting it is less volatile than the broader market. Over the past 52 weeks, the stock has ranged between $55.45 and $113.99. The 50-day moving average is $101.99, and the 200-day moving average is $84.97.

Recent Earnings

Mesa Laboratories reported revenues of $249.13 million, showing a growth of 2.6%. The company achieved a net margin of 2.69% and a return on equity of 3.88%. Earnings per share (EPS) stood at $1.21. Investors are looking forward to the next earnings report, scheduled for August 5, 2026.

Dividend

Mesa Laboratories pays an annual dividend of $0.64 per share, which currently yields 0.67%. The company's dividend payout ratio is approximately 52.9%.

Insider Buying and Selling at Mesa Laboratories, Inc.

In addition to John Sakys's recent purchase, there were other insider activities. On June 22, 2026, Brian David Archbold, SVP of Operations, sold 2,516 shares at $89.50 per share. On the same day, Sakys sold 2,827 shares at the same price. Earlier, on June 18, 2026, Archbold bought 1,859 shares at $95.10 per share.

Analysts Set New Price Targets

On February 4, 2026, Wells Fargo maintained its 'hold' rating on Mesa Laboratories with a price target of $94. The consensus among analysts is a mean target price of $112, based on two analyst opinions.

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, designs and manufactures quality control products for various industries. It operates in sectors like sterilization and disinfection control, clinical genomics, biopharmaceutical development, and calibration solutions. The company serves clients in North America, Europe, and Asia-Pacific, providing tools that ensure the effectiveness of sterilization and disinfection processes, genetic analysis, protein analysis, and environmental monitoring.

Bottom Line

CFO John Sakys's purchase of Mesa Laboratories shares highlights insider confidence in the company's future. Investors keep a close watch on such transactions as they can provide insights into the company's prospects. As always, it's important to remember that insider trades are just one factor to consider when evaluating a stock.